FAVORABLE LONG-TERM SURVIVAL FOLLOWING INDUCTION CHEMOTHERAPY WITH CISPLATIN, FLUOROURACIL, AND LEUCOVORIN AND CONCOMITANT CHEMORADIOTHERAPY FOR LOCALLY ADVANCED HEAD AND NECK-CANCER

被引:103
作者
VOKES, EE
WEICHSELBAUM, RR
MICK, R
MCEVILLY, JM
HARAF, DJ
PANJE, WR
机构
[1] UNIV CHICAGO, PRITZKER SCH MED, DEPT MED, HEMATOL ONCOL SECT, CHICAGO, IL 60637 USA
[2] UNIV CHICAGO, PRITZKER SCH MED, DEPT RADIAT & CELLULAR ONCOL, CHICAGO, IL 60637 USA
[3] UNIV CHICAGO, PRITZKER SCH MED, DEPT SURG, OTOLARYNGOL HEAD & NECK SURG SECT, CHICAGO, IL 60637 USA
来源
JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE | 1992年 / 84卷 / 11期
关键词
D O I
10.1093/jnci/84.11.877
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Background: The majority of patients with head and neck cancer die of locoregional recurrence of disease following surgery and/or radiotherapy. Purpose: Our purpose was to administer induction chemotherapy, perform surgery, and administer concomitant chemoradiotherapy in rapid sequence and to evaluate their impact on locoregional and distant tumor control. Methods: Sixty-four patients with previously untreated, locoregionally advanced head and neck cancer received two cycles of cisplatin, bleomycin, and methotrexate (PBM) (33 patients) or cisplatin, fluorouracil (5-FU), and leucovorin (PFL) (31 patients). PFL was given to patients who were unable to receive bleomycin. Local therapy consisted of surgery and/or concomitant chemoradiotherapy with 5-FU, hydroxyurea, leucovorin, and radiotherapy (FHX-L), all administered every other week. Results: Complete and overall induction response rates were 21% and 79%, respectively, for PBM and 29% and 81%, respectively, for PFL. At completion of local therapy, 81% of the patients were disease-free. With a median follow-up of 35 months, the median survival and time to progression are 22 and 17 months, respectively, for PBM and have not been reached for PFL. Locoregional recurrence of disease is 30% for PBM and 26% for PFL. Distant disease progression is 24% for PBM and only 3% for PFL. Conclusions: The sequencing of induction chemotherapy and concomitant chemoradiotherapy is feasible and results in a high local control rate and in an encouraging survival rate with PFL. The high distant failure (i.e, outside the head and neck area) rate of PBM suggests insufficient systemic activity for that regimen. Implications: Concomitant FHX-L chemoradiotherapy may improve regional control rates of advanced head and neck cancer. Effective systemic therapy may be needed to control systemic micrometastases. PFL, but not PBM, appears to be suitable to accomplish that goal.
引用
收藏
页码:877 / 882
页数:6
相关论文
共 48 条
[1]  
[Anonymous], 1987, CANCER-AM CANCER SOC, V60, P301
[2]   PHASE-I AND PHASE-II TRIAL OF 5-DAY INFUSED 5-FLUOROURACIL AND RADIATION IN ADVANCED CANCER OF THE HEAD AND NECK [J].
BYFIELD, JE ;
SHARP, TR ;
FRANKEL, SS ;
TANG, SG ;
CALLIPARI, FB .
JOURNAL OF CLINICAL ONCOLOGY, 1984, 2 (05) :406-413
[3]  
Chabner B., 1990, CANC CHEMOTHERAPY PR, P341
[4]  
CLARK JR, 1989, SEMIN ONCOL, V16, P44
[5]  
COX DR, 1972, J R STAT SOC B, V34, P187
[6]  
Draper N.R, 1998, APPL REGRESSION ANAL, V326, DOI 10.1002/9781118625590
[7]   CONTINUOUS INFUSION HIGH-DOSE LEUCOVORIN WITH 5-FLUOROURACIL AND CISPLATIN FOR UNTREATED STAGE-IV CARCINOMA OF THE HEAD AND NECK [J].
DREYFUSS, AI ;
CLARK, JR ;
WRIGHT, JE ;
NORRIS, CM ;
BUSSE, PM ;
LUCARINI, JW ;
FALLON, BG ;
CASEY, D ;
ANDERSEN, JW ;
KLEIN, R ;
ROSOWSKY, A ;
MILLER, D ;
FREI, E .
ANNALS OF INTERNAL MEDICINE, 1990, 112 (03) :167-172
[8]   AN ANALYSIS OF INDUCTION AND ADJUVANT CHEMOTHERAPY IN THE MULTIDISCIPLINARY TREATMENT OF SQUAMOUS-CELL CARCINOMA OF THE HEAD AND NECK [J].
ERVIN, TJ ;
CLARK, JR ;
WEICHSELBAUM, RR ;
FALLON, BG ;
MILLER, D ;
FABIAN, RL ;
POSNER, MR ;
NORRIS, CM ;
TUTTLE, SA ;
SCHOENFELD, DA ;
PRICE, KN ;
FREI, E .
JOURNAL OF CLINICAL ONCOLOGY, 1987, 5 (01) :10-20
[9]   RANDOMIZED TRIALS OF INDUCTION CHEMOTHERAPY - A CRITICAL-REVIEW [J].
FORASTIERE, AA .
HEMATOLOGY-ONCOLOGY CLINICS OF NORTH AMERICA, 1991, 5 (04) :725-736
[10]  
FRANKFURT OS, 1973, CANCER RES, V33, P1043